Tuesday September 19th 2017

Sema4A inhibits the therapeutic effect of IFN-β in EAE

In this study, we investigated whether recombinant Sema4A abrogates the efficacy of IFN-β in mice with experimental autoimmune encephalomyelitis (EAE), an animal model of MS. Administration of Sema4A concurrently with IFN-β diminished the efficacy of IFN-β in EAE. These effects of Sema4A were attributed to promote Th1 and Th17 differentiation and to increase adhesive activation of T cells to endothelial cells, even in the presence of IFN-β.Highlights: (Source: Journal of Neuroimmunology)

MedWorm Sponsor Message: Find the best Christmas Sales, Boxing Day Sales and January Sales here.

Originally posted here: 

Sema4A inhibits the therapeutic effect of IFN-β in EAE

Leave a Comment

More from category

Scientists discover markers for progressive multiple sclerosis
Scientists discover markers for progressive multiple sclerosis

Scientists have uncovered two closely related cytokines -- molecules involved in cell communication and movement -- [Read More]

Study uncovers markers for severe form of multiple sclerosis
Study uncovers markers for severe form of multiple sclerosis

Scientists have uncovered two molecules involved in cell communication and movement that may explain why some people [Read More]

Costly drugs to weigh on U.S. employers’ expenses in 2018: survey
Costly drugs to weigh on U.S. employers’ expenses in 2018: survey

(Reuters) - U.S. employers are bracing for higher health care expenses in 2018 as spending on new drugs to treat [Read More]

TG Therapeutics commences enrolment for Phase III multiple sclerosis trials
TG Therapeutics commences enrolment for Phase III multiple sclerosis trials

US-based biopharmaceutical firm TG Therapeutics has commenced enrolment for the Phase III ULTIMATE clinical programme [Read More]

Therapy could offer new hope for MS patients
Therapy could offer new hope for MS patients

Multiple sclerosis sufferer Roy Palmer and his wife Helen (pictured) are desperate for him to be able to walk again. [Read More]